Zogenix to Participate in the 20th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Zogenix, a biopharmaceutical company focused on rare diseases, will participate in the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021. Stephen J. Farr, Ph.D., CEO, and Michael Smith, CFO, are scheduled for a fireside chat at 11:00 AM ET. The event will be available via a live webcast and will be archived for 90 days on the Zogenix Investor Relations website. Zogenix is known for the FDA-approved therapy FINTEPLA® for Dravet syndrome and is also developing treatments for Lennox-Gastaut syndrome and TK2 deficiency.

EMERYVILLE, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Executive Vice President, Chief Financial Officer, and Treasurer, will participate in a fireside chat on Monday, April 12, 2021, at the 20^th Annual Needham Virtual Healthcare Conference.

Zogenix Presentation Details
Date:	Monday, April 12, 2021
Time:	11:00 AM Eastern Time

The presentation will be webcast live and archived for 90 days on Zogenix's Investor Relations website at https://zogenixinc.gcs-web.com.

About Zogenix
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA^® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.

CONTACTS:

Zogenix
Melinda Baker
Senior Director, Corporate Communications
+1 (510) 788-8732 | corpcomms@zogenix.com

Investors
Brian Ritchie 
Managing Director, LifeSci Advisors LLC
+1 (212) 915-2578 | britchie@lifesciadvisors.com

Media
Stefanie Tuck, Vice President, Porter Novelli
+1 (978) 390-1394 | stefanie.tuck@porternovelli.com

FAQ

What is Zogenix presenting at the Needham Virtual Healthcare Conference?

Zogenix will discuss its developments in rare disease therapies, including FINTEPLA® for epilepsy.

When is Zogenix's presentation scheduled?

The presentation is scheduled for April 12, 2021, at 11:00 AM Eastern Time.

How can I access the Zogenix conference presentation?

The presentation will be webcast live and archived on Zogenix's Investor Relations website.

What therapies is Zogenix developing?

Zogenix is developing therapies for Dravet syndrome, Lennox-Gastaut syndrome, and TK2 deficiency.

Is FINTEPLA® approved for use?

Yes, FINTEPLA® has been approved by the U.S. FDA and the European Medicines Agency.